AA amyloidosis is an emerging cause of nephropathy in obese patients
Katia Stankovic Stojanovic1, Sophie Georgin-Lavialle2, Christine Poitou3
1Assistance publique-hôpitaux de Paris, hôpital Tenon, Centre de référence adulte des amyloses d'origine inflammatoire et de la fièvre méditerranéenne familiale (CERAIF), service de médecine interne, F-75020 Paris, France; Sorbonne Universités, UPMC Université Paris 06, Département hospitalo-universitaire I2B, F-75013 Paris, France.
No abstract available in PubMed .
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
10:17An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Related Concept Videos
Nephrotic Syndrome I : Introduction
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
